BCL2 and breast carcinoma: Two bioactive compounds, 2,4,7-trinitrofluorenone (−9.20 Kcal/mol) and 3α, 5α-cyclo-ergosta-7,9(11),22t-triene-6β-ol (−9.50 Kcal/mol), demonstrated better binding affinities against the anti-apoptotic protein receptor (Bcl-2) of breast cancer as compared to the standard drug Venetoclax (−10.90 Kcal/mol).